<DOC>
	<DOCNO>NCT02290470</DOCNO>
	<brief_summary>This randomize , pilot study explore activity olanzapine without delayed dexamethasone prevention delay nausea vomit woman gynecologic cancer receive combination carboplatin paclitaxel . Women treat regimen particularly susceptible chemotherapy-induced nausea vomiting . Given anti-emetic prophylaxis olanzapine may increase control delay symptom woman receive carboplatin paclitaxel .</brief_summary>
	<brief_title>Olanzapine Against Delayed Nausea Vomiting Women Receiving Carboplatin Plus Paclitaxel</brief_title>
	<detailed_description>The purpose study ass use olanzapine improve control delay nausea vomit woman receive combination carboplatin paclitaxel gynaecologic cancer . Patients randomize one three treatment arm . Please see `` Arms Intervention '' section detail information . The primary objective determine treatment group proportion patient achieve Complete Protection ( CP ; vomit , rescue anti-emetics , mild nausea ) delay phase ( day 2-5 post-chemotherapy ) first chemotherapy cycle . The secondary objective : 1 . To determine proportion patient achieve Complete Response ( CR ; vomit , rescue anti-emetics ) acute ( day 1 post-chemotherapy ) , delay , overall ( day 1-5 post-chemotherapy ) period . 2 . To determine incidence potential toxicity ascribe olanzapine . 3 . To assess impact nausea vomit daily life activity treatment group . Protocol treatment begin ≤14 day registration . Patients receive treatment Days 1-3 . Patients permit take rescue therapy treat investigator 's choice base clinical circumstance . After complete treatment , patient monitor side effect .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Histologically cytologically document gynaecologic cancer Patients chemotherapy naive schedule receive 1day moderately emetogenic chemotherapy ( carboplatin Area Curve ( AUC ) 5 plus paclitaxel ) . Women , 18 year old Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Adequate organ system function , define follow : bone marrow : absolute neutrophil count &gt; =1,500/L , platelets &gt; =100,000/L liver : bilirubin 1.5 x upper limit normal ( ULN ) ; transaminases &lt; =2.5 x ULN kidney : creatinine &lt; =1.5 x ULN • Able take oral medication psychiatric illness social situation would preclude study compliance history central nervous system ( e.g. , brain metastasis , seizure disorder ) Positive pregnancy test registration . treatment antiemetic medication 24 hour 5 day treatment . treatment another antipsychotic agent risperidone , quetiapine , clozapine , phenothiazine , butyrophenone 30 day protocol therapy . concurrent abdominal radiation therapy . concurrent quinolone antibiotic therapy . know hypersensitivity olanzapine . vomit and/or significant nausea ( &gt; = Common Toxicity Criteria Adverse Events ( CTCAE ) grade 2 ) within 24 hour begin chemotherapy . another organic cause nausea vomit unrelated chemotherapy administration . chronic alcoholism ( determined investigator ) . know cardiac arrhythmia , uncontrolled congestive heart failure acute myocardial infarction within previous 6 month . history uncontrolled diabetes mellitus .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>